At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 464 enrolled
Drug / intervention
ACT-128800 Dose 1 +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate the Efficacy, Safety, and Tolerability of Three Doses of ACT-128800, an Oral S1P1 Receptor Agonist, Administered for Twenty-four Weeks in Patients With Relapsing-remitting Multiple Sclerosis
In Brief
A Phase 2 clinical trial evaluating ACT-128800 Dose 1, Placebo, and 2 other interventions for Multiple Sclerosis. Completed, enrolled 464 participants across 115 sites in 23 countries.
Detailed Summary
This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Sclerosis
CountriesAustralia, Austria, Belgium, Bulgaria, Canada, Czechia, Finland, France, Germany, Hungary, Israel, Italy, Netherlands, Poland, Romania, Russia, Serbia, Spain, Sweden, Switzerland, Ukraine, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedNov 2009
Primary CompletionJun 2011
Study CompletionJul 2011
TodayJul 2026
First PostedNov 2, 2009
Enrollment StartOct 1, 2009
Primary CompletionJun 1, 2011
Study CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 16.7 years ago
Interventions
ACT-128800 Dose 1drug
ACT-128800 (Dose 1) administered orally once daily
Placebodrug
Matching placebo administered orally once daily
ACT-128800 Dose 2drug
ACT-128800 (Dose 2) administered orally once daily
ACT-128800 Dose 3drug
ACT-128800 (Dose 3) administered orally once daily